CJC-1295 NO DAC + Ipamorelin

This blend pairs a GHRH analog with a selective GH secretagogue to amplify physiologic, pulsatile growth‑hormone (GH) signaling. CJC‑1295 (no DAC) is described as a modified GHRH fragment that stimulates the pituitary to release GH, with human data showing sustained, dose‑dependent increases in GH and IGF‑1 after subcutaneous dosing. Ipamorelin is presented as a ghrelin‑mimetic pentapeptide that triggers a relatively fast GH pulse (peaking within about an hour) but—importantly—does so with minimal stimulation of ACTH/cortisol/prolactin compared with less selective secretagogues. Because the two agents act through different receptor systems (GHRH receptor vs GHS‑R1a), the protocol frames the combination as synergistic: CJC helps ‘prime’ GHRH signaling while ipamorelin adds a clean secretagogue pulse. The intended outcome is steadier GH/IGF‑1 support while still respecting natural pulsatility rather than continuous exposure.